Objective: To analyze the cost-effectiveness of a meningococcal C vaccination program in Brazil. Methods: A hypothetical cohort of 3,194,038 children born in Brazil in 2006 was followed for 10 years. A decision tree model was developed using the TreeAge Pro 2007 software program to compare universal infant vaccination with the current program. Epidemiological and cost estimates were based on data retrieved from National Health Information Systems and the literature. The analysis was conducted from the public health care system and societal perspectives. Costs are expressed in 2006 Brazilian reals (R$). Results: At 94% coverage, the program would avoid 1,218 cases, 210 deaths, and 14,473 life-years lost, a reduction of, respectively, 45%, 44%, and 44%, for the 10-year period. Vaccination costs of R$320.9 million would not be offset by R$4 to R$7.9 million decreases in disease treatment costs. A national vaccination program would cost R$21,620 per life-year saved from the perspective of the health-care system and R$21,896 per life-year saved from society's perspective. Results were most sensitive to case fatality rate, disease incidence, and vaccine cost. Conclusions: A universal childhood vaccination program against meningococcal C proved to be a cost-effective strategy, supporting the recent decision of the Brazilian government. These results could contribute to defining the most favorable price of the vaccine and to monitoring its impact on the population.
Introduction
Meningococcal disease (MD) is a major health problem worldwide. In Brazil, MD is endemic, with occasional circumscribed outbreaks. Four major epidemics occurred in the 20th century, the last one was a serogroup B epidemic that lasted from the late 1980s to the early 2000s [1, 2] . In recent years, MD incidence rates have returned to the historical endemic threshold of around 2 cases per 100,000 inhabitants. Children younger than 5 years of age are the most affected age group, with the highest incidence rates in the first year of life [3, 4] . In the past decade, a progressive increase in the proportion of cases caused by serogroup C has been observed in the country [4, 5] . In 2008, approximately 68% of MD cases were due to serogroup C. Early initiation of antibiotic therapy and clinical management in intensive care environment allowed for a reduction in mortality related to MD; however, the disease still has a high case fatality rate and risk of serious sequelae, particularly in developing countries [1, 6] . Vaccination is considered the best prevention and control strategy for MD [7] .
Meningococcal C conjugate (MenCC) and meningococcal A ϩ C polysaccharide vaccines are available at the Brazilian public health-care system for outbreak control and immunization of individuals at high risk of invasive disease caused by Neisseria meningitides [8] . The vaccines are also available through the private health-care system, with low population coverage. This strategy resulted in very low vaccine coverage; less than 5% of children younger than 5 years of age received at least one dose of MenCC in 2009. In September 2010, MenCC was introduced into the routine immunization schedule of infants (three doses at 3, 5, and 12 months) with catch-up vaccination for children younger than 2 years of age.
The objective of this economic evaluation was to analyze the cost-effectiveness of a MenCC universal vaccination program for children younger than 1 year of age in Brazil.
Methods

Model design
A deterministic decision tree model for cost-effectiveness analysis was developed (TreeAge Pro 2007 software program, TreeAge Software Inc., Williamstown, MA) to compare universal infant MenCC vaccination to the alternative strategy of vaccinating only highrisk individuals (Fig. 1) . A hypothetical cohort of 3, 194 ,038 children born in Brazil in 2006 was studied for a 10-year period after the introduction of a routine MenCC vaccination program.
The model was based on endemic threshold incidence rates of MD and the proportion of cases caused by serogroup C in the past decade without considering the possibility of an epidemic. The 10-year period was chosen primarily because around 62% of cases of MD occur in children younger than 10 years of age but also because of the uncertain behavior of the MD epidemiology. Because epidemics and the causal serogroup are difficult to predict, a static model with a very long time horizon could deviate too much from a scenario that would probably include outbreaks.
The analysis compared two strategies: universal infant vaccination with MenCC and an alternative strategy of vaccination of a high-risk population. According to the diagram of the model (Fig.  1) , the universal vaccination strategy considers two alternatives: vaccinated and nonvaccinated individuals, depending on vaccination coverage. In the vaccinated arm, the vaccine may protect or not. Protection depends on vaccine effectiveness and the proportion of disease caused by serogroup C and was considered to remain stable in the first 2 years after vaccination. In the third year, a proportion of children will lose protection. Those who continue to be protected at the third year will remain so (no meningococcal disease) until the end of the analyzed period. In those who lose protection in the third year, MD may or may not develop (clone 1) and may progress to cure or death. The survivors may or may not have sequelae. Those in whom MD did not develop in the third year may remain disease free or MD may develop in the fourth year by repeating the outcomes described, and so on until the 10th year. MD may or may not develop in children unprotected in the first year after vaccination. In those who finish the year without MD, there is a chance that the disease will develop in the next year. The same chain of events repeats until the 10th year (represented in the clone 2).
In the nonvaccinated arm of the universal vaccination strategy, the starting event will be the same as that described for the group of unprotected children in the first year of vaccination (clone 2).
In the alternative strategy, children follow the same flow of events described in the nonvaccinated arm of the universal vaccination strategy (clone 2).
This model estimates the burden of disease caused by all meningococcal serogroups and calculates the number of cases of serogroup C disease avoided by the vaccine. Under universal vaccination, MD patients have the same outcomes as those in the alternative strategy, but in different proportions, depending on vaccination coverage, vaccine effectiveness, and proportion of MD caused by serogroup C. Herd protection conferred by the vaccine was not considered in the model.
The economic analysis was performed from the perspective of both the public health-care system (Sistema Único de Saúde) and society. The public health-care system perspective included the direct medical costs (medical visits, hospital admissions, laboratory tests, and imaging studies, and medications). The societal perspective included direct medical costs, direct nonmedical costs (transportation to health services), and the indirect costs related to caregiver work loss. Costs were estimated in Brazilian reals at 2006 prices (US$1.00 ϭ R$2.098). Future costs and consequences were discounted at 5% per year, as recommended [9] . Univariate and multivariate sensitivity analyses were performed for selected variables, and ranges of variation were determined by the literature and the authors' assumptions. Best and worst case scenario analyses were conducted. The worst case scenario assumed the lowest rates of vaccine protection in the first and second years, the lowest MD incidence and case fatality rates, and a 50% higher vaccine price (R$48.64 per dose). The best case scenario assumed the highest rates of vaccine protection in the first and second years, the highest MD incidence and case fatality rates, and a 50% lower vaccine price (R$16.22 per dose). Other parameter estimates remained the same as the base case. A probability sensitivity analysis (PSA) was conducted. The purpose of a PSA is to explore the implications of parameter uncertainty for the results of cost-effectiveness analyses [10] . The uncertainty surrounding important parameters such as vaccine protection in the first and second years (vaccine effectiveness ϫ percentage of MD due to serogroup C), MD incidence, and case fatality rates and cost per vaccine dose was explored using Monte Carlo simulation (1000 interactions), which randomly chooses values from the parameter distributions to jointly estimate costs and effects of each strategy. In this analysis, uniform distributions were applied to serogroup coverage (percentage of MD due to serogroup C), MD incidence, case fatality rate, vaccine dose cost, and log normal for vaccine effectiveness, as recommended elsewhere [11] . The means, SDs, and minimum and maximum values used to estimate the parameters for the distributions are reported in Table 1 . The results of the PSA are presented as the confidence interval for the incremental cost-effectiveness ratio (ICER) and as cost-effectiveness acceptability curves.
Vaccination strategy
In the universal vaccination strategy, the infants will receive three doses of MenCC (two doses in the first semester of life and a booster dose in the second year). It was assumed that the vaccine would be administered simultaneously with other vaccines that are part of the Brazilian infant immunization schedule.
The MenCC vaccination coverage rate was assumed to be 94% based on data from a recent household survey that estimated vaccination coverage with three doses of DTP-Hib vaccine (recommended at 2, 4, and 6 months of life) of 94% [12] . It was assumed that vaccination coverage will be constant in the entire period of analysis. Based on administrative data for doses administered in 2006, MMR (measles, mumps, rubella) vaccine coverage is Ͼ95%. So, it was also assumed that all children initiating vaccination will receive the complete three-dose schedule. Based on published data, vaccine effectiveness against serogroup C was estimated to be 95% in the first 2 years post-vaccination, with a 10% loss in vaccine-induced protection in the third year, and remaining stable thereafter [13] [14] [15] [16] [17] . Adverse events post-MenCC vaccines are rare and usually mild and were not taken into account in this analysis [16] . Catch-up vaccination of susceptible older children was also not considered.
It was assumed that all vaccinations would be carried out through the public health-care system. Vaccine price was assumed to be R$32.43 per dose, paid by the Brazilian National Immunization Program (NIP) in 2006. In the absence of national data, administration cost per dose was assumed to be R$2.098 (US$1.00), following methodology used in a previous study [18] . The vaccine wastage rate was set at 5% considering a single-dose package, as recommended by World Health Organization (WHO) when estimating the number of needed doses to introduce a new vaccine into an NIP [19] .
Epidemiological data
The MD incidence rates were estimated based on the number of confirmed cases of disease reported to the Notifiable Diseases Information System (Sistema de Informação de Agravos de Notificação [SINAN]) in 2006. The SINAN database contains national data on frequency and outcomes (cure or death) of MD, according to age group and clinical syndromes (meningitis, meningococcemia, or meningitis with meningococcemia) [20] .
In Brazil, the pathogen is not identified in a large proportion of bacterial meningitis (BM). In São Paulo state, with better health-care coverage, most (58%) episodes of BM in children younger than 10 years of age were reported to SINAN as "unspecified BM" in 2006. N. meningitidis was responsible for 36.3% of BM with the identified causative microorganism in this age group [21] . Assuming that 1) the proportion of cases of BM with identified pathogens in other states would be similar to that in São Paulo and 2) the proportion of meningococcal meningitis among cases of unspecified BM would be similar to the observed in cases of BM with an identified pathogen, we estimated the numbers of episodes of meningococcal meningitis reported under the diagnosis of unspecified BM. These numbers were added to the confirmed cases of MD to obtain the estimate for the total numbers of MD.
Age-specific incidence rates were calculated using population estimates for Brazil in 2006, based on the 2000 Brazilian Census, for age groups younger than 1 year, 1 to 4 years, and 5 to 9 years (Table 1) [22] . Case-fatality rates by age groups were calculated based on confirmed cases and deaths reported to SINAN (Table 1) . Life-years lost were calculated by subtracting the age at which the death would occur from the age groupspecific life expectancy in Brazil.
It was assumed that survivors of MD could have skin necrosis, amputation, neurological sequelae, deafness, or no sequelae. Sequelae rates were assumed by the authors based on those in the literature (Table 1 ) [23] [24] [25] [26] .
National data from SIREVA II (Network Surveillance System for the Bacterial Agents Responsible for Pneumonia and Meningitis) was used to determine the proportion of MD caused by serogroup C in Brazil (Table 1 ) [5] .
Cost data
It was assumed that all patients were hospitalized and that each patient would require one emergency department visit before hospital admission and one follow-up visit after discharge. The proportions of hospital admissions through the public (77%) and private (23%) health-care systems were taken from a 2003 national household survey (Pesquisa Nacional por Amostra de Domicílios) [27] .
Costs for hospital admissions in the public sector were obtained from the Hospital Information System (Sistema de Informação Hospitalar) [28] . The private sector hospitalization costs were obtained from the Tabela Única Nacional de Equivalência de Procedimentos, TUNEP), a reference table used by the National Health Agency (Agência Nacional de Saúde) for the reimbursement of procedures performed by the Sistema Único de Saúde (SUS) for the private prepaid health plans clients [29] . Costs for ambulatory treatments were obtained from the Ambulatory Information System (Sistema de Informação Ambulatorial) and the TUNEP [29, 30] .
Based on data from the state of São Paulo SINAN database, it was assumed that each MD case would lead to chemoprophylaxis for 10 close contacts of the patient. This assumption was also present in other studies of economic evaluation [31, 32] . It was assumed that all contacts would receive rifampicin and the adult dose (8 capsules of 300 mg per person) was used to estimate its costs. The estimated cost of chemoprophylaxis per MD case was R$15.20 (R$0.19 ϫ 8 capsules ϫ 10 contacts).
Children with sequelae incurred sequelae-specific procedure costs in addition to costs related to acute MD. The estimated costs of neurological sequelae were based on annual reference costs of care for children with encephalopathy in a specialized institution.
Treatment costs for deafness were not included because no national data exist as a basis for reasonable estimates of the costs of diagnosis and treatment of deafness in the Brazilian population in general, not in children or in children who have deafness as a sequela of meningococcal meningitis.
Nonmedical direct costs were included in the analysis from the societal perspective. Transportation costs were calculated based on unit cost of the average cost of public transportation in Brazil in 2006 (R$1.89) and the number of visits needed during treatment.
The Human Capital Method was adopted to estimate indirect costs, included in the analysis from the perspective of society. In this study, indirect costs represent the work time lost by mothers of children acutely ill with MD or with neurological sequelae. The analysis followed children from 0 to 10 years old and added the costs of lost productivity by parents caring for their children with sequelae until 10 years of age. Costs of lost productivity of patients with sequelae in adulthood were not included. in the health-care system perspective. In the society perspective, they also include transport (case and family) and caregiver productivity losses. § From the perspective of society, the annual treatment of neurological sequelae includes sequelae treatment (R$8,052.96) and productivity loss of parents (R$11,101.44), the base case showed the value of R$19,154.40. The low value was R$9,577.20 (Ϫ50%) and high value was R$28,731.60 (ϩ50%). In the perspective of the health-care system, the annual treatment of neurological sequelae includes only the treatment of sequelae.
The base case showed the value of R$8,052.96, the low value was R$4,026.48 (Ϫ50%) and high value was R$12,079.44 (ϩ50%).
Results
Disease burden and costs of MD
The model estimated that with the alternative strategy (vaccination of high-risk persons), 2,728 children of the 2006 birth cohort would acquire MD and 474 of them would die in the 10-year period. These cases would result in R$23 million in total costs, including R$18,386,760 in treatment costs and R$4,698,445 in vaccination costs ( Table 2) .
The universal MenCC vaccination program, at 94% coverage, would prevent 1,218 cases and 210 deaths, allowing a gain of 14,473 life-years, a reduction in disease outcomes of, respectively, 45%, 44%, and 44% for the 10-year period. Universal vaccination of infants would cost R$320 million more than the alternative strategy, with a R$7.9 million reduction in disease treatment costs, resulting in ICERs of R$256,903 per case avoided and R$21,620 per life-year saved (LYS) from the perspective of society. From the perspective of the health-care system, universal vaccination would result in ICERs of R$260,182 per case avoided and R$21,896 per LYS (Table 2) . When a discount rate of 5% per year was applied for both health and monetary effects, the ICERs were R$24,804 and R$25,088 per LYS, respectively, from the society and health-care system perspectives.
Sensitivity analysis
In a deterministic one-way sensitivity analysis, nine key parameters were varied. The ICERs were most sensitive to variations in vaccine protection in the first and second years followed by case fatality rates, disease incidence rates, and cost per vaccine dose (Fig. 2) . When the lowest percentage of MD due to serogroup C (0.20) was used to calculate the vaccine protection in the first and second years (vaccine effectiveness ϫ percentage of MD due to serogroup C), incremental cost per LYS increased by 222% (to R$69,622). When case fatality rates of all age groups were decreased simultaneously to the lowest estimates, the incremental cost per LYS increased by 103% (to R$44,024). With the lowest MD incidence rates in the past 10 years, there was an approximate increase of 51% in the ICER, and with the highest rates, there was an approximate decrease of 56% in the ICER.
Increases or decreases in price per vaccine dose had a direct proportional impact on the ICERs. Figure 3shows the range of values for ICERs per LYS at different prices per vaccine dose.
Increases in hospital treatment costs and neurological sequelae treatment costs did not affect cost-effectiveness ratios.
In the multivariate sensitivity analysis, the ICER varied from R$1,919 per LYS for the best case scenario to R$313,660 for the worst case.
The probabilistic sensitivity analysis indicated that the 95% confidence interval around the ICER (R$21,620 per LYS) was R$5,704 to R$58,758. The probability that universal infant vaccination program is cost-effective over a range of willingness-to-pay values is shown in Figure 4 .For a threshold value of approximately R$38,000 (three gross domestic products [GDPs] per capita per disability-adjusted life-year [DALY] averted) [33] , the probability that universal infant vaccination program is cost-effective is 87.3%. At a threshold of approximately R$12,688 (one GDP per capita per DALY averted) [33] , the probability that universal infant vaccination program is cost-effective is 27.7%.
Discussion
In this study, universal MenCC vaccination for Brazilian infants can be considered a cost-effective intervention when applying the ICERs, incremental cost-effectiveness ratios; LYS, life-year saved. * Alternative strategy, vaccination of children at high risk of disease. WHO threshold-an intervention costing less than three GDPs per capita per DALY saved can be considered cost-effective (2006 Brazilian GDP per capita ϭ R$12,688) [33] . Using LYS (which considers only mortality) instead of DALY saved (which considers both mortality and morbidity) as an outcome makes this analysis very conservative. The vaccine would be certainly more cost-effective if disability was taken into account. This result puts the recent decision of the Brazilian government in a favorable perspective, although ICER threshold values cannot be used as absolute parameters when economic evaluations are part of policy-making processes [34] .
MD causes great fear in the population due to its sudden onset, rapid progress, high case fatality, and epidemic potential. The existence of a vaccine to prevent MD generates strong demands from the population and health-care workers for its introduction into the NIPs. These ethical concerns play a key role in decision making and are not part of a cost-effectiveness analysis [35] . The economic evaluation of a prevention technology for MD has limitations as a tool to support decision making, given that its methodological assumptions imply the need for predictability of the disease after the introduction of the vaccine, and epidemics are, by definition, unanticipated, intense, and frightening events requiring that public health managers perform specific interventions. The study of the vaccine against MenCC presents a particular challenge. As the analysis is based on a situation of relative epidemiology stability of endemic disease, it may lose its relevance very quickly, given the possibility of sudden change in the epidemiological context.
Although there were available data on the number of MD outbreaks in Brazil, this study's costs included only estimates for MenCC vaccine used to contain these outbreaks (included in the total vaccine doses per year in the alternative strategy) and chemoprophylaxis for patients' contacts because no additional information was available for the costs of other public health measures to control an epidemic, which may be high. Assuming that universal childhood vaccination is able to avoid epidemics, not including these costs, biases the results of the analyses against the vaccination program [35] . Only two economic evaluations of the MenCC vaccine reported in the literature, however, sought to introduce epidemic outbreaks in their analysis [32, 37] .
When estimating epidemiological and cost parameters, this study optimized the use of existing health information systems, supplemented with data obtained from careful review of the literature. Prioritizing national epidemiological data when available may have contributed to underestimation, and this conservative perspective was considered in the sensitivity analysis. A correction strategy was adopted to include a number of episodes of meningococcal meningitis estimated to be reported under the diagnosis unspecified BM, a significant proportion of BM cases reported to SINAN. In São Paulo state, during the past 5 years, the proportion of meningococcal meningitis among BM cases increased in parallel with the increase in the proportion of cases with identification of the causative pathogen, supporting this correction strategy [38] . Nevertheless, it was not possible to propose a correction strategy for misdiagnosis and underreporting to SINAN, despite some evidence pointing to its importance [39] .
The measurement of the frequency and intensity of sequelae was even more difficult, given the lack of national standardized data. Deafness, in particular, was more underestimated because it is treated essentially on an outpatient care basis, for which available administrative data are scarce.
However, approaches to the incorporation of utility weights in economic evaluations of MD have several limitations, including lack of country-specific weights for complications and sequelae of MD and transferability. Most of the published studies used one of two sources of utility information [31] . Pharmacoeconomic guidelines state that utility values obtained from other countries are, in general, not transferable because of cultural differences [40] . In Brazil, utility weights are not available, and utilities from other countries would need to be considered. We analyzed carefully the data sources and instruments used to collect these data and decided that utility values from the mid-1990s in Canada [31] or developed by a panel of Dutch physicians [41, 42] would not be transferable to the Brazilian setting.
An additional complication is the fact that the target population (children younger than 10 years old) of our study is unable to provide utilities with instruments originally developed for adults. Children are often regarded as unreliable respondents [43] , and the methodology of quality of life measurement in young children is still in its infancy [42] . Based on these arguments, we preferred to be conservative and did not include quality of life in our analysis, avoiding the use of a parameter subject to a great deal of uncertainty and a potential effect on the cost-effectiveness ratio favoring the introduction of MenCC vaccine.
Regarding cost estimates, the cost methodology adopted, the top-down approach, based on official information of reimbursement rates, tends to be conservative, but has the advantage of offering a national perspective and greater comparability with other studies. The methodological implications of this decision were also considered in the sensitivity analysis. Because national data were not available, the costs of treatment and rehabilitation of deafness were not included, and these costs may be substantial.
An important limitation is that the lifetime sequelae-specific medical costs were not included in the analysis. Only the sequelae-specific procedure costs of the 10-year period of the analysis were considered. For neurological sequelae, the cost of long-term residential care and special education were not included. Because deafness treatment was not considered, cochlear implant and lifetime costs related to its placement and maintenance were also not accounted for in costs.
The inclusion of indirect costs significantly improves the chances of demonstrating the cost-effectiveness of the MenCC vaccine because indirect costs related to patient productivity losses may exceed direct medical costs by a factor of Ն2 when calculated by the human capital approach [35] . Because our decision analysis model followed one birth cohort for 10 years, the indirect costs included in the analysis were restricted to work time lost by mothers due to caregiving and calculated using average salary rates. Most importantly, the lifetime productivity reduction in survivors with sequelae and their caregivers was not included in the analysis because our time horizon was 10 years. This is one of the possible explanations for the very similar results of the two perspectives.
Another limitation was the estimate of vaccine administration costs, for which no Brazilian data are available. Two other vaccines were recently introduced into the immunization schedule of Brazilian infants: the human monovalent rotavirus vaccine in 2006 and the 10-valent pneumococcal conjugate vaccine in March 2010. These vaccines, as well as the MenCC vaccine, are available in a one-dose package demanding a huge space in the cold chain structure. The costs of strengthening the cold chain all over the country to allow for the introduction of these new vaccines have not been considered in this study, but are certainly important. Furthermore, the immunization schedule adopted by the NIP (at 3, 5, and 12 months of age) requires two additional visits to administer the MenCC vaccine. In this analysis, we assumed that the vaccine would be administered simultaneously with other vaccines already included in the infant schedule, and so the costs of these additional visits were not considered.
Costs of adverse events associated with vaccination were also not considered because they are rare.
Vaccination programs may provide indirect effects. Individuals in the target population who are not vaccinated and the unvaccinated contacts of immunized individuals outside the target vaccination cohort (e.g., household relatives of immunized children) may receive protection from the disease via the immunization of others and the reduced transmission in the community. This phenomenon is described by the term herd protection [35] . A decision tree static model was used in this study, and static models may underestimate the benefits of the vaccination program by failing to consider its indirect effects (herd protection), resulting in higher values of ICERs. Large-scale immunization programs in Canada, Spain, and the UK evidenced strong herd protection effects associated with MenCC vaccine [15] [16] [17] . Only one study, however, used a dynamic model to evaluate cost-effectiveness of an infant meningococcal vaccination program because of the difficulty of developing the model and its parameterization [44,] . Moreover, herd protection was observed in countries where catch-up vaccination was extended to adolescents and young adults. In Brazil, considering the local MD epidemiology and the vaccine's availability, MenCC vaccine is routinely administered only to children younger than 2 years old.
The cost-effectiveness of any vaccination program will be greatly influenced by the choice of the alternative program(s) being evaluated. Failure to recognize the inefficiency of a comparator strategy may lead to inaccurate and overly optimistic estimates of cost-effectiveness [35] . In our cost-effectiveness analysis, we compared the new strategy with the existing program (vaccination of high-risk population), and the costs and benefits of this option were explicitly calculated. The choice of the comparison program was based on local MD epidemiology, with the majority of cases occurring in the first year of life.
The most important factors that affected the ICER in the sensitivity analysis were estimates of the vaccine protection in the first and second years, case fatality and incidence rates of MD, and vaccine cost. The epidemiological estimates are heavily dependent on the pathogen and population characteristics and may change suddenly and unpredictably. Vaccine prices always affect ICERs of immunization programs in developing countries. There is great potential for change in the vaccine's price, depending on general economic and political factors and scientific and technological policies. In 2007 and 2008, the price paid by the Brazilian NIP for the MenCC vaccine ranged from R$26 to R$30 per dose which is slightly below that used in this study (R$32.43). Negotiations between the Brazilian Ministry of Health and the manufacturer for the introduction of the vaccine into the NIP set its price at R$19 per dose. At this price, the ICER of the universal vaccination program in this study, all other things equal, will be R$12,844 per LYS, in the society's perspective, very close to the threshold of a very cost-effective intervention, according to WHO criteria of less than one GDP per capita per DALY avoided (Fig. 3) [33] . This ICER of R$12,844 per LYS for the MenCC universal vaccination program is similar to those found in studies of vaccines recently incorporated into the routine of the NIP such as rotavirus (R$1,028) [45] , pneumococcus (R$22,066) 46, and a vaccine against varicella, not yet incorporated (R$14,749) [47] .
The budgetary impact of incorporating the MenCC vaccine immediately after the introduction of the pneumococcal conjugate vaccine is very important when considering the values of the 2009 Brazilian NIP budget. The Ministry of Health invested R$552 million to buy the 10-valent pneumococcal and the MenCC vaccines in 2010, representing 66.2% of the 2009 NIP budget (R$833.5 million) to carry out all immunizations for the whole Brazilian population. Introducing two new vaccines into the NIP in such a short time is a challenge and will require significant additional investments in health-care personnel, training, and cold chain infrastructure.
